Celerion Launches Enhanced Version of Labnotes Bioanalytical Data Management Software

LINCOLN, Neb.; May 6, 2025 (Business Wire) – Celerion, a global leader in early clinical research and bioanalytical services, announced the launch of the latest version of Labnotes, its cutting-edge bioanalytical electronic laboratory notebook software elevating data handling and analysis capabilities for sponsors.

The latest system enhancements streamline laboratory documentation and improve operational efficiency for users. The updated platform also offers advanced tools for handling and organizing large datasets, ensuring faster processing of reports and optimized database queries.

“With this enhanced version, Celerion underscores its commitment to expanding the use of cutting-edge technology to support its clients in achieving business success,” said Chad Briscoe, Executive Vice President of Global Bioanalytical Services at Celerion. “These improvements demonstrate our continued commitment to innovation and excellence in all facets of our laboratory operations.”

Celerion also introduced robust features to support security and flexibility. Enhanced encryption and secure access controls guarantee data protection, while new archiving and extraction tools enable secure data sharing without requiring the core software. Additionally, the inclusion of a Report API allows seamless integration with external reporting tools, providing users with tailored reporting capabilities to meet their specific needs.

“Our approach to software development is rooted in customer feedback and the latest industry trends. The updates in Labnotes empower clients with robust tools to manage and analyze their data effectively, enabling better decision-making and driving impactful business outcomes," said Mark Williams, CEO of Terrington Data Management.

About Celerion

Celerion, a global leader in early clinical research, offers clients expert-driven services that enable fast, informed decisions in drug development. With over 50 years of experience, Celerion specializes in Phase 1 studies, including first-in-human dose escalation, drug-drug interactions, cardiac safety, bioequivalence, metabolism, and pharmacokinetics in patient populations. Celerion also provides comprehensive data management, biostatistics, clinical monitoring, and bioanalytical services. For more information, visit www.celerion.com.